We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+13.44%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$329M
AUM Growth
+$94M
Cap. Flow
+$80.7M
Cap. Flow %
24.51%
Top 10 Hldgs %
27.28%
Holding
112
New
38
Increased
35
Reduced
8
Closed
25

Top Buys

Rank Stock Value
1
NVS icon
Novartis
NVS
+$7.49M
2
KTWO
K2M Group Holdings, Inc
KTWO
+$6.3M
3
SYK icon
Stryker
SYK
+$5.17M
4
MEDP icon
Medpace
MEDP
+$4.63M
5
ABT icon
Abbott
ABT
+$4.5M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$6.94M
2
BMY icon
Bristol-Myers Squibb
BMY
+$6.34M
3
UHS icon
Universal Health Services
UHS
+$5.36M
4
MCK icon
McKesson
MCK
+$5.13M
5
ACH
Accendra Health
ACH
+$4.16M

Sector Composition

Rank Sector Weight
1 Healthcare 62.31%
2 Financials 2.43%
3 Industrials 2.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
51
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$2.74M 0.83%
+151,250
New +$2.96M
AVGR
52
DELISTED
Avinger, Inc. Common Stock
AVGR
$2.73M 0.83%
+5
New +$3.3M
SPNC
53
DELISTED
Spectranetics Corp
SPNC
$2.51M 0.76%
100,000
-75,000
-43% -$1.75M
AGN
54
DELISTED
Allergan plc
AGN
$2.48M 0.75%
10,750
+2,830
+36% +$692K
SRPT icon
55
Sarepta Therapeutics
SRPT
$1.9B
$2.46M 0.75%
+40,000
New +$1.21M
NXTM
56
CALL
DELISTED
NxStage Medical Inc.
NXTM
$2.43M 0.74%
+97,100
New +$2.26M
THC icon
57
Tenet Healthcare
THC
$21B
$2.38M 0.72%
+105,000
New +$2.73M
SGYP
58
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$2.27M 0.69%
412,500
+62,500
+18% +$293K
VIVE
59
DELISTED
VIVEVE MED INC
VIVE
$2.26M 0.69%
313
-56
-15% -$372K
KITE
60
PUT
DELISTED
Kite Pharma, Inc.
KITE
$2.21M 0.67%
+39,500
New +$2.2M
ISEE
61
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.96M 0.6%
42,500
-10,000
-19% -$564K
NSTG
62
DELISTED
NanoString Technologies, Inc.
NSTG
$1.94M 0.59%
+96,986
New +$1.54M
EXAS
63
CALL
DELISTED
Exact Sciences
EXAS
$1.86M 0.56%
+100,000
New +$1.76M
ISEE
64
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.72M 0.52%
37,200
+12,200
+49% +$688K
DCOY
65
Decoy Therapeutics
DCOY
$2.05M
– –
0
– –
AMRN
66
Amarin Corp
AMRN
$297M
$1.51M 0.46%
23,750
-30,625
-56% -$1.72M
FOMX
67
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.27M 0.39%
137,000
+35,000
+34% +$293K
RDUS
68
DELISTED
Radius Health, Inc.
RDUS
$1.07M 0.32%
+19,775
New +$1M
RCKT icon
69
Rocket Pharmaceuticals
RCKT
$378M
$1.06M 0.32%
27,867
+9,117
+49% +$287K
IMMU
70
DELISTED
Immunomedics Inc
IMMU
$1.04M 0.32%
319,565
+202,822
+174% +$567K
HZNP
71
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$907K 0.28%
+50,000
New +$977K
ALDX icon
72
Aldeyra Therapeutics
ALDX
$91.1M
$892K 0.27%
114,067
+36,567
+47% +$223K
DMK
73
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$875K 0.27%
3,643
+1,422
+64% +$296K
FPRX
74
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$787K 0.24%
15,000
+1,750
+13% +$83.6K
WMGIZ
75
DELISTED
Wright Medical Group, Inc. Contingent Value Right
WMGIZ
$769K 0.23%
586,936
– –
1 2
3
4 5

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q3 2016 Portfolio in Review

As of Q3 2016, Pura Vida Investments held 112 positions worth $329M, up 40% from $235M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Pura Vida Investments deployed $80.7M of net new capital in Q3 2016, opening 38 new positions and adding to 35 existing holdings. Its largest new stake was Novartis: 102,812 shares worth $7.27M.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 63% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Insulet, an estimated $2.8M trimmed.

  • Pura Vida Investments's largest Q3 2016 buy was Novartis: 102,812 shares worth $7.27M.
  • Pura Vida Investments added most to Stryker in Q3 2016, an estimated $5.17M increase.
  • Pura Vida Investments's biggest Q3 2016 reduction was Insulet, cutting an estimated $2.8M.
  • Pura Vida Investments fully exited Medtronic in Q3 2016, selling an estimated $6.94M.
  • Pura Vida Investments's ten largest holdings make up 27% of its $329M portfolio in Q3 2016.
  • Pura Vida Investments opened 38 new positions and closed 25 in Q3 2016.
  • Pura Vida Investments's portfolio value rose 40% quarter-over-quarter to $329M.

Based on Pura Vida Investments's 13F filing for Q3 2016, filed 14 Nov 2016.